The analysis of the economic affordability of a range of restrictive lists of medicines used for the treatment of neoplasms class diseases

This research covers the analysis of the economic affordability of the range of drugs for the treatment of neoplasms class diseases included in the restrictive lists of drugs. A positive dynamics of growth in the incidence of neoplasms was recorded, the leading position in the growth of the number of diseases is occupied by Oryol region, where average rate of increase (ΔRincr) is 9 %. The number of antineoplastic drugs used in the treatment of diseases of class C00-D48 CLASS II Neoplasms included in the list of vital and essential drugs in 2019 totalled to 781 drugs. When analyzing the price range of this array of drugs, it was revealed that 69.4 % of antineoplastic drugs are in the price range over 1,000 rubles. An analysis of economic availability of antineoplastic drugs showed that the best value of the integral indicator of the availability coefficients are for Cyclophosphan-LENS®, Fluorouracil-Teva, Rubomycin (ONOPB JSC), the least available were: Vargatef, Imbruvika, Tafinlar. The integral indicators of availability coefficients of the researched drugs range from 0.443 (Cyclophosphan-LENS®) to 6531.884 (Vargatef). The analysis of the economic affordability of the range of restrictive lists of drugs used for the treatment of neoplasm class diseases is an important aspect of the activity, which makes it possible to give an objective assessment of the work of executive authorities and entities in the sphere of drug circulation in the formation of an affordable range of restrictive lists of drugs.

1. Ukaz Prezidenta RF ot 7 maya 2018 g. N 204 “O nacional’nyh celyah i strategicheskih zadachah razvitiya Rossijskoj Federacii na period do 2024 goda”.

2. Prikaz Ministerstva zdravoohraneniya Rossijskoj Federacii ot 13.02.2013 № 66 “Ob utverzhdenii Strategii lekarstvennogo obespecheniya naseleniya Rossijskoj Federacii na period do 2025 goda i plana ee realizacii”.

3. Oficial’nyj sajt federal’noj sluzhby gosudarstvennoj statistiki RF. [Elektronnyj resurs] – URL: http://www.gks.ru

4. Maksimkina E.A. Gosudarstvennaya politika v oblasti lekarstvennogo obespecheniya naseleniya Rossijskoj Federacii //Novaya apteka – 2014. – № 6. – S. 13-14.

5. Prasolov A.V., Kolbin A.S., Maksimkina E.A., Golant Z.M., Kurylev A.A. i soavt. Modelirovanie vklyucheniya lekarstvennyh sredstv v ogranichitel’nye perechni (primer – ZHNVLP). Analiz dannyh 2014 goda. Remedium. 2015;4:58-63.

6. Prasolov A.V., Kolbin A.S., Maksimkina E.A., Golant Z.M.. Kurylev A.A. i soavt. Analiz Perechnya zhiznenno neobhodimyh i vazhnejshih lekarstvennyh preparatov (ZHNVLP) 2014 goda s pomoshch’yu matematicheskogo modelirovaniya. Medicinskie tekhnologii. Ocenka i vybor. 2015;4: 13-19.

7. Ulumbekova G.E., Kalashnikova A.V. Podhody k formirovaniyu koncepcii nacional’noj lekarstvennoj politiki. CHast’ 1. Analiz rynka lekarstvennyh preparatov v RF. ORGZDRAV: novosti, mneniya, obuchenie. Vestnik VSHOUZ. 2018; 4: 53-75.

8. Tel’nova, E.A. Assortimentnaya politika kak element dostupnosti i kachestva lekarstvennoj pomoshchi / E.A. Tel’nova, G.N. Gil’deeva // Remedium. – 2007. – № 7. – S. 14-20.

9. Garankina R. Y., Zakharochkina E. R., Samoshchenkova I. F., Lebedeva N. Y., Lebedev A. V. Blockchain Technology and Its Use in the Area of Circulation of Pharmaceuticals // Journal of Pharmaceutical Sciences and Research – 2018. – T. 10 (11). – S. 2715-2717.

10. Garankina R.Y., Vaskova L.B., Tiapkina M.V., Sologova S.S., Smirnov A.I., Samoshchenkova I.F. Analysis Of The Economic Affordability Of Antiviral Medicines Included In The Restrictive Lists Of Medicines // Systematic Reviews in Pharmacy. – 2020. – T.11, N12. – S. 1108-1116.

11. Federal’nyj zakon № 61-FZ ot 12.04.2010 (red. ot 06.06.2019) «Ob obrashchenii lekarstvennyh sredstv».

12. Postanovleniya Pravitel’stva RF ot 28.08.2014 N 871 (red. ot 20.11.2018) «Ob utverzhdenii Pravil formirovaniya perechnej lekarstvennyh preparatov dlya medicinskogo primeneniya i minimal’nogo assortimenta lekarstvennyh preparatov, neobhodimyh dlya okazaniya medicinskoj pomoshchi».

13. Samoshchenkova I. F., Kachmarskaya L. M., Snimschikova I. A., Garankina R.Y., Bekhorashvili N. U. A system of adaptive management of a pharmacy’s list of essential medicines // Research J. Pharm. and Tech.- 2019. – № 12 (12). – S. 5739-5744.

14. Kolbin A.S., Prasolov A.V., Maksimkina E.A., Polushin YU.S., Kurylev A.A. i soavt. Modeli analiza vklyuchenij lekarstvennyh sredstv v ogranichitel’nye perechni (na primere ZHNVLP) 2016 g. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya. 2016;1: 39-43.

15. Perechni zhiznenno neobhodimyh i vazhnejshih lekarstvennyh preparatov dlya medicinskogo primeneniya. [Elektronnyj resurs] – URL: https://base.garant.ru/72123048/

16. Svistunov, A.A. Osobennosti provedeniya farmakoekonomicheskogo analiza pri razlichnyh nozologiyah / A.A. Svistunov, R.I. YAgudina, V.V. Babij i dr. // Sechenovskij vestnik. – 2016. – T.24, № 2. – S.42–50.

17. Samoshchenkova I.F., Buvina I.V., Garankina R.YU. Analiz obyazatel’nogo minimal’nogo assortimenta aptechnyh organizacij s pozicii importozameshcheniya na rossijskom farmacevticheskom rynke // APRIORI: Elektronnyj nauchnyj zhurnal – 2016. URL: https://elibrary.ru/item.asp?id=26020173

18. Garankina R. Y., Zakharochkina E. R., Samoshchenkova I. F., Kachmarskaya L. M., Lebedev A.V. Marketing analysis of the required drugs in pharmacies // Journal of Advanced Pharmacy Education & Research – Oktyabr’-dekabr’ 2019. – T. 9. – C. 76-82.

19. Rejhtman, T.V. Sovremennye problemy perechnej lekarstvennyh sredstv (preparatov), dejstvuyushchih v Rossijskoj Federacii / T.V. Rejhtman, L.V. Moshkova // Nauchnye vedomosti BelGU, Seriya Medicina. Farmaciya. – 2014. – № 18 (189), vypusk 27. S.189-195.

20. Samoshchenkova I.F., Lebedeva H.YU., Garankina R.YU. Analiz ekonomicheskoj dostupnosti minimal’nogo assortimenta aptechnoj organizacii // Remedium. – 2016. – № 12. – C. 66-70.

21. YAgudina, R.I. Modelirovanie vyzhivaemosti v farmakoekonomicheskih issledovaniyah: model’Markova i model’ razdelyonnoj vyzhivaemosti / R.I. YAgudina, V.V. Babij // Farmakoekonomika: teoriya i praktika. – 2017. – T.5, № 2. – S.13-17.

22. YAgudina, R.I. Kriterii effektivnosti v farmakoekonomicheskom analize / R.I. YAgudina, V.G. Serpik, V.V. Babij i dr. // Farmakoekonomika: teoriya i praktika. – 2017. – T.5, № 3. – S.5-10.

23. Samoshchenkova I.F., Kachmarskaya L.M., Bobkova E.A., Hmarina A.K. Farmakoekonomicheskij analiz kak instrument sovershenstvovaniya ekonomicheskoj dostupnosti assortimenta lekarstvennogo obespecheniya // Nauchno-prakticheskij zhurnal «Ekonomicheskie i gumanitarnye nauki» – 2021– № 2(349). – S. 77-87.

24. Samoshchenkova I.F., Lebedev A.V., Garankina R.YU. Opredelenie finansovoj nagruzki na aptechnuyu organizaciyu pri vvedenii lekarstvennogo preparata v minimal’nyj assortiment // Farmaciya. – 2016. – T. 65, № 8. – C. 39-44.

25. Samoshchenkova I.F., Garankina R.YU., Lebedev A.V., Bobkova E.A., Omel’chenko A.A. Analiz struktury assortimenta ogranichitel’nyh perechnej lekarstvennyh preparatov, primenyaemyh dlya lecheniya zabolevanij klassa novoobrazovaniya // Vestnik Smolenskoj gosudarstvennoj medicinskoj akademii – 2020, T. 19, № 4. – S. 183-191

26. Rejhtman, T.V. Ocenka dostupnosti lekarstvennoj pomoshchi naseleniyu na razlichnyh etapah ee okazaniya / T.V. Rejhtman, L.V. Moshkova // Nauchnye vedomosti BelGU, Seriya: Medicina, Farmaciya. – 2014. – № 24(195). S.144-150.